Biotech

Peregrine Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Recent Developments

TUSTIN, CA: Positive Phase IIb Data in Second-Line NSCLC and FDA Agreement on Pivotal Phase III Trial Design Position Start of Phase III Trial by Calendar Year-End; Bavituximab's Immunotherapeutic Mechanism ...

China Investing Billions in Bid to Catch Up With Western Pharma

BOSTON, MA: The Asian Giant Has Invested a Staggering $160 Billion on Biomedicine, and Is Poised to Surpass Japan and Emerge the Second-Largest Spender on R&D, as It Sets Ambitious Targets for Drug Developmen ...

ProMetic's Lead Drug Candidate, PBI-4050, on Track to Enter Clinical Trial Program in September 2013

LAVAL, QUEBEC: - New data confirms potential novel therapy for diabetic kidney diseases (DKD), chronic kidney diseases (CKD) and pulmonary fibrosis. ...

BIOSENTA Signs National Sales and Distribution Agreement With International Sales & Marketing Services Firm-CROSSMARK Canada

TORONTO, ONTARIO: ...

Theratechnologies Announces Financial Results for Second Quarter of 2013

MONTREAL, CANADA: ...

Genetic Technologies Announces U.S. Patent Office Allows First Patent for ImmunAid

MELBOURNE, AUSTRALIA: ...

Bio-Solutions Corporation Launches www.Type2Defense.com to Take Online Orders

SAN ANTONIO, TEXAS: ...

United States Food and Drug Administration Accepts Trimel's NDA for CompleoTRT(TM)

TORONTO, ONTARIO: ...

Sernova Receives Patent Allowance for Therapeutic Immune Privileged Cell Technologies

LONDON, ONTARIO: ...

Theratechnologies Inc./Request for Reconsideration in Canada: Meeting With Scientific Advisory Committee Authorized

MONTREAL, QUEBEC: ...